Next Article in Journal
Assessing the Attitudes and Clinical Practices of Ohio Dentists Treating Patients with Dental Anxiety
Next Article in Special Issue
Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)
Previous Article in Journal
Marginal Vertical Fit along the Implant-Abutment Interface: A Microscope Qualitative Analysis
Previous Article in Special Issue
Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Dentistry Journal
Volume 4
Issue 4
10.3390/dj4040032
dentistry-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma

by
Petra Rugani
1,*,
Christian Walter
2,
Barbara Kirnbauer
1,
Stephan Acham
1,
Yvonne Begus-Nahrman
3 and
Norbert Jakse
1
1
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria
2
Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany
3
Konzept Pharma Service GmbH, 31084 Freden, Germany
*
Author to whom correspondence should be addressed.
Dent. J. 2016, 4(4), 32; https://doi.org/10.3390/dj4040032
Submission received: 2 August 2016 / Revised: 27 August 2016 / Accepted: 19 September 2016 / Published: 27 September 2016
(This article belongs to the Special Issue New Cancer and Osteoporosis Therapies and Osteocrosis of the Jaws)
Browse Figures
Versions Notes

Abstract

:
Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.

1. Introduction

In 2003 Robert E. Marx reported on 36 cases of non-healing painful bone exposure in the mandible, maxilla, or both, that were unresponsive to surgical or medical treatments in patients treated with bisphosphonates as a growing epidemic [1].
This causal association was cautiously denied in a letter by Tarassof and Csermak representing Novartis, given the fact that no such reports had occurred in multiple, well-controlled clinical trials of more than 3000 cancer patients that had been conducted as far back as the early 1990s [2].
To date jaw necrosis linked to antiresorptive therapy is an accepted side effect and no longer a matter of discussion.
In 2007 bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been primarily defined as a condition of exposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks in patients who have received or are receiving treatment with bisphosphonates and have no history of radiation therapy of the jaws [3]. This definition relies on a combination of various symptoms in combination with the patient’s anamnesis. Even though the condition was firstly described over ten years ago, the underlying principles of pathogenesis are not conclusively clarified yet. Common theories deal with reduced bone remodeling, impairment of local vascularization, and neoangiogenesis [4], accumulation of microcracks in devitalized bone with empty osteocyte lacunae [5], and infection of bone via osteoclast-independent bone resorption [6,7].
Three stages were specified, the main symptom being frank bone exposure in the maxillofacial region [8]. In addition, an “at-risk category” was defined for patients who have been treated with either oral or intravenous bisphosphonates, but show no apparent exposed/necrotic bone.
As experience grew in this condition, clinicians recognized that bisphosphonate-exposed patients can show clinical and radiological signs potentially indicating osteonecrosis lacking the cardinal symptom of exposed bone in the maxillofacial region. Therefore, the AAOMS updated its classification and added a stage 0 category, implying patients who show nonspecific clinical and radiological findings or symptoms that possibly correlate to osteonecrosis. These findings must not be explicable by other conditions [3]. As a study by Fedele et al. showed that patients who present BRONJ stage 0 may be at high risk of developing advanced stages of BRONJ [9], the relevance of an early diagnosis increased. It has to be mentioned that the AAOMS classification of 2009 categorized bone exposure via fistulas stage 0, implying that no invasive treatment is needed in such cases. This was revised in 2013, when each bony exposure fulfilling the criteria was counted as evident bone necrosis, no matter the extent. Furthermore, the term BRONJ was changed to MRONJ (medication-related osteonecrosis of the jaw) taking into account other pharmaceuticals that might cause jaw necrosis besides bisphosphonates.
Consequently, published prevalences of BRONJ were steadily increasing [10,11,12,13] since this update from 2009 and 2013, augmented by MRONJ cases due to therapy with Denosumab, or antiangiogenic agents like Bevazicumab or Sunitinib.
In general the incidence rate is higher in patients with intravenous administration of bisphosphonates compared to the oral route of administration. The estimates of MRONJ for intravenous application range from around 1% [14,15] to 21% for sub-clienteles [16], but even after more than 10 years since this condition was reported there is still some lack of knowledge. The main reasons therefore are probably:
Many patients are asymptomatic for a long time and, thus, may not be diagnosed or do not relate their oral symptoms to the antiresorptive therapy.
People suffering from MRONJ have various underlying diseases. They present a heterogeneous group of patients treated by independent medical specialists. A standardized oral investigation of patients at risk has still not been implemented to date. As a consequence, the definite prevalence might be higher, as demonstrated by Walter et al. [16], who showed that prevalence of BRONJ is underestimated if thorough inspection of the oral cavity is omitted.
The condition is influenced by several risk factors, such as drug potency, type of administration, as well as individual local and systemic conditions. In many cases patients receive multiple agents that interfere with bone metabolism and may, therefore, cause or benefit the development of osteonecrosis.

2. Objectives

To review published prevalences of ONJ in patients with the primary diseases of breast cancer, prostate cancer, and multiple myeloma, receiving parenteral antiresorptive therapy (bisphosphonates, denosumab).

3. Methods

We performed a PubMed literature search using the terms: “osteonecrosis”, “incidence”, “prevalence”, “bisphosphonate”, and “denosumab”.
Inclusion criteria were: the type of primary cancer: breast cancer, multiple myeloma, or prostate cancer; parenteral antiresorptive therapy with bisphosphonate or denosumab; and a size of patient collective of at least 10 patients.
Exclusion criteria were: review papers; duplicated articles; integrated analyses of already reported studies; and animal studies.
The reports were screened for prevalence rates, and data concerning primary disease and used antiresorptive therapy were collected.
Data analysis was performed concerning the following questions:
  • What is the prevalence of osteonecrosis (ONJ) relating to primary disease?
  • What are the prevalences before and after the adaptions of the AAOMS classification in 2009?
To assess the overall ONJ prevalence patients were grouped according to primary disease. Thus, positive ONJ cases were weighted against the total number of patients of all included studies.

4. Results

One-hundred forty-one articles were found. Fifty-eight papers were excluded right away after screening of abstracts because of improper article type (review papers, case reports, prevalence not reported) or inappropriate primary disease (osteoporosis, rheumatoid arthritis, giant cell carcinoma, other cancer types).
Fifteen further manuscripts were excluded after studying the full papers. The reasons therefore were:
  • Study population not described in sufficient detail;
  • Primary disease for each ONJ case not assignable;
  • Oral administration route;
  • Double reports;
  • Combined analysis of other trials;
  • Estimation of prevalence; and
  • Special risk situation due to performed intervention.
Sixty-eight reports comprising 29,437 patients were included in the analysis (Table 1).
Amongst those, 41 were published before 2009 (13,059 patients) and 27 since 2010 (16,378 patients). Of the total patients, 16,632 suffered from breast cancer, 4236 from prostate cancer, and 8569 from multiple myeloma.
Nine-hundred fifty-one cases of jaw necrosis were described. Amongst those, 348 had breast cancer, 161 had prostate cancer, and 442 suffered from multiple myeloma (Table 2).
Thus, the overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.
Published prevalences in patients with breast cancer range from 0 to 26.7% (median 2.6%), from 0 to 20.9% (median 4.8%) in prostate cancer patients, and from 0 to 20.5% (median 5.1%) in patients with multiple myeloma (Figure 1).
Overall prevalence in all patients published until 2009 ranges from 0 to 18.6% (median 3.6%) and from 0 to 26.7% (median 3.7%) in papers published since 2010 (Figure 2).

5. Discussion

In this paper we determined the weighted prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma, including 69 reports comprising 29,670 patients. Prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.
To the best of our knowledge there are three further reports addressing this issue. In 2009 Walter et al. [46] provided an overview including 25 studies from 2005 to 2008 comprising 5825 patients and reported on lower prevalences in breast cancer patients compared to prostate cancer and multiple myeloma patients. In 2010 Walter et al. [16] also addressed the problem of possible under-reporting of MRONJ cases if dental examinations are left out. In 2014 Boquete-Castro et al. published a systemic analysis evaluating the adverse advents of Denosumab [82]. They found seven articles reporting on 97 MRONJ cases. Incidences were low and ranged between 0 and 2%, but exceeded the incidences in the zoledronate control group. Published prevalences of medication-related osteonecrosis of the jaw show a great range. Possible explanations have been discussed in the literature and may include variations in sample size, varying methods of data assessment/analysis, and limitations due to voluntary case reporting [65]. Furthermore, when evaluating the published literature we had to realize that in most papers MRONJ definition is not clearly stated. Very often descriptions are not detailed and do not refer to a specific classification system, or are even left out completely.
Despite this inhomogeneity it has been shown that the application of zoledronic acid produces a greater risk than the use of pamidronate or the combination of zoledronate and pamidronate [25]. Additionally, ONJ onset seems to be earlier among patients receiving zoledronic acid as compared to patients receiving pamidronate [18], and even later if alendronate or risedronate is used [25,83,84].
Regarding denosumab, ONJ prevalence was slightly higher compared with zoledronate, but no significant difference was found [70].
In general, ONJ develops more frequently if parenteral administration of antiresorptive agents are used [85,86,87] and significantly correlates with the number of applied doses [12,53,65]. Differences in applied dosing protocols may also be the reason for the discrepancy of ONJ prevalences in patients with different primary diseases, resulting in a higher risk for patients suffering from multiple myeloma (weighted ONJ-prevalence 5.16%) compared to patients with breast cancer (weighted ONJ prevalence 2.09%).
Beyond that several additional factors influencing the risk of MRONJ have been identified.
Concomitant oral disease, respectively, oral inflammation, may increase the risk of ONJ [14,67], as well as wearing of dentures [47] and anatomical circumstances. ONJ occurs more frequently in the mandible with described predilection for the molar and premolar region, as well as regions with thin mucosal coverage, like tori or the mylohyoid line [70,87,88].
Oral surgery, and above all, dental extractions, are most frequently named to increase ONJ risk around seven- to more than ten-fold [14,20,53,70,89].
Taylor et al., who reviewed the clinical records of 225 patients at risk who underwent dental extraction, identified eight ONJ cases out of 23 (34.8%) patients prescribed intravenous bisphosphonates and five ONJ cases in 202 patients (2.5%) with oral bisphosphonate administration [90]. However, the periodontal and inflammation status in the surrounding bone might be a more important factor in the development of osteonecrosis rather than the procedure of the extraction itself [91].
In addition, systemic risk factors have been described. ONJ onset seems to be more frequent in women and in advanced age [17,86,87,88]. This might be attributed to the fact that important primary diseases, like breast cancer and osteoporosis, are more frequent in women, respectively, and that cancer and osteoporosis commonly develop with increasing age. Regarding the group of multiple myeloma patients, no difference in gender could be detected [20,25,50,87].
Furthermore, the wearing of removable mucosa-retained dentures also becomes more likely with increasing age and is a known risk factor. Patients with removable dentures are more likely to develop osteonecrosis compared to patients with fixed partial dentures and patients without substitution of potentially messing teeth [92].
Concomitant medical therapy may enhance ONJ risk, which has been particularly reported for corticosteroids and antiangiogenic therapy. A correlation to chemotherapy, diabetes, or anaemia is less substantiated [12,20,25,70], although a recently published article sees an association to a pathological glucose metabolism [93]. Altogether, systemic risk factors seem to have less impact than local variables [70].
Finally, differences in diagnostic criteria, mainly resulting from differences or alterations in classification guidelines, may also have an impact, albeit we could not detect a difference in published prevalences until 2009 compared to those since 2010, after the revision of AAOMS guidelines. It could be hypothesized that intensifying oral inspections to detect early forms (Stage 0) and possibly including patients presenting sinus tracts into verified ONJ cases, resulted in a higher prevalence as already demonstrated [63]. However, this effect might be compensated by the greater awareness towards ONJ risk and, consequently, the implementation of preventive measures. Routine dental prevention to eliminate potential sites of infection prior to antiresorptive treatment and managing risk factors in patients at risk reduces the BRONJ rate, as already described in the literature [12,50,52,94,95]. Furthermore, it has been reported that dental extraction and oral surgery are quite safe if certain rules are obeyed [13,15,96,97].

6. Conclusions

The exact pathogenic mechanisms of MRONJ development are still unknown, but risk factors have been described. Patients with malignant diseases carry a relevant risk for MRONJ. It has been shown that it is possible to reduce ONJ risk by implementation of routine dental preventive measures and management of known risk factors. Consequently, a close cooperation between medical specialties involved in the treatment of malignoma and multiple myeloma patients at risk is crucial to minimize ONJ prevalence.

Acknowledgments

Statistical evaluation performed by Clemens Keil, [email protected].

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115–1117. [Google Scholar] [CrossRef]
  2. Tarassoff, P.; Csermak, K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J. Oral Maxillofac. Surg. 2003, 61, 1238–1239. [Google Scholar] [CrossRef] [PubMed]
  3. Ruggiero, S.L.; Dodson, T.B.; Assael, L.A.; Landesberg, R.; Marx, R.E.; Mehrotra, B.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J. Oral Maxillofac. Surg. 2009, 67, S2–S12. [Google Scholar]
  4. Ziebart, T.; Pabst, A.; Klein, M.O.; Kammerer, P.; Gauss, L.; Brullmann, D.; Al-Nawas, B.; Walter, C. Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin. Oral Investig. 2011, 15, 105–111. [Google Scholar] [CrossRef] [PubMed]
  5. Hoefert, S.; Schmitz, I.; Tannapfel, A.; Eufinger, H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: A possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin. Oral Investig. 2010, 14, 271–284. [Google Scholar] [CrossRef] [PubMed]
  6. Rustemeyer, J.; Bremerich, A. Bisphosphonate-associated osteonecrosis of the jaw: What do we currently know? A survey of knowledge given in the recent literature. Clin. Oral Investig. 2010, 14, 59–64. [Google Scholar] [CrossRef] [PubMed]
  7. Allen, M.R.; Burr, D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. J. Oral Maxillofac. Surg. 2009, 67, S61–S70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2007, 65, 369–376. [Google Scholar]
  9. Fedele, S.; Porter, S.R.; D’Aiuto, F.; Aljohani, S.; Vescovi, P.; Manfredi, M.; Arduino, P.G.; Broccoletti, R.; Musciotto, A.; Di Fede, O.; et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series. Am. J. Med. 2010, 123, 1060–1064. [Google Scholar] [CrossRef] [PubMed]
  10. Almăşan, H.A.; Băciut, M.; Rotaru, H.; Bran, S.; Almăşan, O.C.; Băciut, G. Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases. Rom. J. Morphol. Embryol. 2011, 52, 1233–1241. [Google Scholar] [PubMed]
  11. Bantis, A.; Zissimopoulos, A.; Sountoulides, P.; Kalaitzis, C.; Giannakopoulos, S.; Deftereos, S.; Tsakaldimis, G.; Thomaidis, V.; Touloupidis, S. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. Tumori 2011, 97, 479–483. [Google Scholar] [PubMed]
  12. Bonacina, R.; Mariani, U.; Villa, F.; Villa, A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients. J. Can. Dent. Assoc. 2011, 77, b147. [Google Scholar] [PubMed]
  13. Schubert, M.; Klatte, I.; Linek, W.; Müller, B.; Döring, K.; Eckelt, U.; Hemprich, A.; Berger, U.; Hendricks, J. The Saxon Bisphosphonate Register—Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 2011, 48, 349–354. [Google Scholar] [CrossRef] [PubMed]
  14. Hoff, A.O.; Toth, B.B.; Altundag, K.; Johnson, M.M.; Warneke, C.L.; Hu, M.; Nooka, A.; Sayegh, G.; Guarneri, V.; Desrouleaux, K.; et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 2008, 23, 826–836. [Google Scholar] [CrossRef] [PubMed]
  15. Mavrokokki, T.; Cheng, A.; Stein, B.; Goss, A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 2007, 65, 415–423. [Google Scholar] [CrossRef] [PubMed]
  16. Walter, C.; Al-Nawas, B.; Frickhofen, N.; Gamm, H.; Beck, J.; Reinsch, L.; Blum, C.; Grötz, K.A.; Wagner, W. Prevalence of bisphosphonate associate osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010, 6, 11. [Google Scholar] [CrossRef] [PubMed]
  17. Bamias, A.; Kastritis, E.; Bamia, C.; Moulopoulos, L.A.; Melakopoulos, I.; Bozas, G.; Koutsoukou, V.; Gika, D.; Anagnostopoulos, A.; Papadimitriou, C.; et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J. Clin. Oncol. 2005, 23, 8580–8587. [Google Scholar] [CrossRef] [PubMed]
  18. Durie, B.G.; Katz, M.; Crowley, J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 2005, 353, 99–102. [Google Scholar] [PubMed]
  19. Guarneri, V.; Donati, S.; Nicolini, M.; Giovannelli, S.; D’Amico, R.; Conte, P.F. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist 2005, 10, 842–848. [Google Scholar] [CrossRef] [PubMed]
  20. Badros, A.; Weikel, D.; Salama, A.; Goloubeva, O.; Schneider, A.; Rapoport, A.; Fenton, R.; Gahres, N.; Sausville, E.; Ord, R.; et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J. Clin. Oncol. 2006, 24, 945–952. [Google Scholar] [CrossRef] [PubMed]
  21. Calvo-Villas, J.M.; Tapia Torres, M.; Govantes Rodríguez, J.; Carreter de Granda, E.; Sicilia Guillén, F. Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid. Med. Clin. 2006, 127, 576–579. [Google Scholar] [CrossRef]
  22. Dimopoulos, M.A.; Kastritis, E.; Anagnostopoulos, A.; Melakopoulos, I.; Gika, D.; Moulopoulos, L.A.; Bamia, C.; Terpos, E.; Tsionos, K.; Bamias, A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006, 91, 968–971. [Google Scholar] [PubMed]
  23. Sanna, G.; Preda, L.; Bruschini, R.; Cossu Rocca, M.; Ferretti, S.; Adamoli, L.; Verri, E.; Franceschelli, L.; Goldhirsch, A.; Nole, F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann. Oncol. 2006, 17, 1512–1516. [Google Scholar] [CrossRef] [PubMed]
  24. Tosi, P.; Zamagni, E.; Cangini, D.; Tacchetti, P.; Di Raimondo, F.; Catalano, L.; D’Arco, A.; Ronconi, S.; Cellini, C.; Offidani, M.; et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006, 108, 3951–3952. [Google Scholar] [CrossRef] [PubMed]
  25. Zervas, K.; Verrou, E.; Teleioudis, Z.; Vahtsevanos, K.; Banti, A.; Mihou, D.; Krikelis, D.; Terpos, E. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in303patients. Br. J. Haematol. 2006, 134, 620–623. [Google Scholar] [CrossRef] [PubMed]
  26. Ortega, C.; Faggiuolo, R.; Vormola, R.; Montemurro, F.; Nanni, D.; Goia, F.; Aglietta, M. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol. 2006, 45, 216–217. [Google Scholar] [CrossRef] [PubMed]
  27. Aguiar Bujanda, D.; Bohn Sarmiento, U.; Cabrera Suarez, M.A.; Aguiar Morales, J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann. Oncol. 2007, 18, 556–560. [Google Scholar] [CrossRef] [PubMed]
  28. Corso, A.; Varettoni, M.; Zappasodi, P.; Klersy, C.; Mangiacavalli, S.; Pica, G.; Lazzarino, M. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007, 21, 1545–1548. [Google Scholar] [CrossRef] [PubMed]
  29. Garcia Saenz, J.A.; Lopez Tarruella, S.; Garcia Paredes, B.; Rodriguez Lajusticia, L.; Villalobos, L.; Diaz Rubio, E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med. Oral Patol. Oral Cir. Bucal 2007, 12, E351–E356. [Google Scholar] [PubMed]
  30. Jadu, F.; Lee, L.; Pharoah, M.; Reece, D.; Wang, L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann. Oncol. 2007, 18, 2015–2019. [Google Scholar] [CrossRef] [PubMed]
  31. Ortega, C.; Montemurro, F.; Faggiuolo, R.; Vormola, R.; Nanni, D.; Goia, F.; Gilardino, M.O.; Aglietta, M. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. Acta Oncol. 2007, 46, 664–668. [Google Scholar] [CrossRef] [PubMed]
  32. Petrucci, M.T.; Gallucci, C.; Agrillo, A.; Mustazza, M.C.; Foa, R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007, 92, 1289–1290. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, E.P.; Kaban, L.B.; Strewler, G.J.; Raje, N.; Troulis, M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg. 2007, 65, 1328–1331. [Google Scholar] [CrossRef] [PubMed]
  34. Lipton, A.; Steger, G.G.; Figueroa, J.; Alvarado, C.; Solal-Celigny, P.; Body, J.J.; de Boer, R.; Berardi, R.; Gascon, P.; Tonkin, K.S.; et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 2007, 25, 4431–4437. [Google Scholar] [CrossRef] [PubMed]
  35. Pozzi, S.; Marcheselli, R.; Sacchi, S.; Baldini, L.; Angrilli, F.; Pennese, E.; Quarta, G.; Stelitano, C.; Caparotti, G.; Luminari, S.; et al. Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk. Lymphoma 2007, 48, 56–64. [Google Scholar] [CrossRef] [PubMed]
  36. Boonyapakorn, T.; Schirmer, I.; Reichart, P.A.; Sturm, I.; Massenkeil, G. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008, 44, 857–869. [Google Scholar] [CrossRef] [PubMed]
  37. Fehm, T.; Beck, V.; Banys, M.; Lipp, H.P.; Hairass, M.; Reinert, S.; Solomayer, E.F.; Wallwiener, D.; Krimmel, M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol. Oncol. 2009, 112, 605–609. [Google Scholar] [CrossRef] [PubMed]
  38. Ibrahim, T.; Barbanti, F.; Giorgio-Marrano, G.; Mercatali, L.; Ronconi, S.; Vicini, C.; Amadori, D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study. Oncologist 2008, 13, 330–336. [Google Scholar] [CrossRef] [PubMed]
  39. Walter, C.; Al-Nawas, B.; Grotz, K.A.; Thomas, C.; Thuroff, J.W.; Zinser, V.; Gamm, H.; Beck, J.; Wagner, W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol. 2008, 54, 1066–1072. [Google Scholar] [CrossRef] [PubMed]
  40. Yonemori, K.; Fujiwara, Y.; Minami, H.; Kitagawa, K.; Fujii, H.; Arai, T.; Sohn, W.; Ohkura, M.; Ohtsu, T. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci. 2008, 99, 1237–1242. [Google Scholar] [CrossRef] [PubMed]
  41. Ellis, G.K.; Bone, H.G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 2008, 26, 4875–4882. [Google Scholar] [CrossRef] [PubMed]
  42. Christodoulou, C.; Pervena, A.; Klouvas, G.; Galani, E.; Falagas, M.E.; Tsakalos, G.; Visvikis, A.; Nikolakopoulou, A.; Acholos, V.; Karapanagiotidis, G.; et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76, 209–211. [Google Scholar] [CrossRef] [PubMed]
  43. Estilo, C.L.; Van Poznak, C.H.; Wiliams, T.; Bohle, G.C.; Lwin, P.T.; Zhou, Q.; Riedel, E.R.; Carlson, D.L.; Schoder, H.; Farooki, A.; et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008, 13, 911–920. [Google Scholar] [CrossRef] [PubMed]
  44. Montefusco, V.; Gay, F.; Spina, F.; Miceli, R.; Maniezzo, M.; Teresa Ambrosini, M.; Farina, L.; Piva, S.; Palumbo, A.; Boccadoro, M.; et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk. Lymphoma 2008, 49, 2156–2162. [Google Scholar] [CrossRef] [PubMed]
  45. Musto, P.; Petrucci, M.T.; Bringhen, S.; Guglielmelli, T.; Caravita, T.; Bongarzoni, V.; Andriani, A.; D’Arena, G.; Balleari, E.; Pietrantuono, G.; et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008, 113, 1588–1595. [Google Scholar] [CrossRef] [PubMed]
  46. Walter, C.; Al-Nawas, B.; Du Bois, A.; Buch, L.; Harter, P.; Grötz, K.A. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009, 115, 1631–1637. [Google Scholar] [CrossRef] [PubMed]
  47. Aragon-Ching, J.B.; Ning, Y.M.; Chen, C.C.; Latham, L.; Guadagnini, J.P.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Parnes, H.; Figg, W.D.; et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investig. 2009, 27, 221–226. [Google Scholar] [CrossRef] [PubMed]
  48. Cetiner, S.; Sucak, G.T.; Kahraman, S.A.; Aki, S.Z.; Kocakahyaoglu, B.; Gultekin, S.E.; Cetiner, M.; Haznedar, R. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J. Bone Miner. Metab. 2009, 27, 435–443. [Google Scholar] [CrossRef] [PubMed]
  49. Crawford, B.S.; McNulty, R.M.; Kraut, E.H.; Turowski, R.C. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer. Cancer Investig. 2009, 27, 984–988. [Google Scholar] [CrossRef] [PubMed]
  50. Dimopoulos, M.A.; Kastritis, E.; Bamia, C.; Melakopoulos, I.; Gika, D.; Roussou, M.; Migkou, M.; Eleftherakis-Papaiakovou, E.; Christoulas, D.; Terpos, E.; et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 2009, 20, 117–120. [Google Scholar] [CrossRef] [PubMed]
  51. Haidar, A.; Jonler, M.; Folkmar, T.B.; Lund, L. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand. J. Urol. Nephrol. 2009, 43, 442–444. [Google Scholar] [CrossRef] [PubMed]
  52. Ripamonti, C.I.; Maniezzo, M.; Campa, T.; Fagnoni, E.; Brunelli, C.; Saibene, G.; Bareggi, C.; Ascani, L.; Cislaghi, E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 2009, 20, 137–145. [Google Scholar] [CrossRef] [PubMed]
  53. Vahtsevanos, K.; Kyrgidis, A.; Verrou, E.; Katadritou, E.; Triaridis, S.; Andreadis, C.G.; Boukovinas, I.; Koloutsos, G.E.; Teleioudis, Z.; Kitikidou, K.; et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 2009, 27, 5356–5362. [Google Scholar] [CrossRef] [PubMed]
  54. Fizazi, K.; Lipton, A.; Mariette, X.; Body, J.J.; Rahim, Y.; Gralow, J.R.; Gao, G.; Wu, L.; Sohn, W.; Jun, S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 2009, 27, 1564–1571. [Google Scholar] [CrossRef] [PubMed]
  55. Bonomi, M.; Nortilli, R.; Molina, A.; Sava, T.; Santo, A.; Caldara, A.; Cetto, G.L. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: A long-term retrospective analysis. Med. Oncol. 2009, 27, 224–229. [Google Scholar] [CrossRef] [PubMed]
  56. Stumpe, M.R.; Chandra, R.K.; Yunus, F.; Samant, S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 2009, 31, 202–206. [Google Scholar] [CrossRef] [PubMed]
  57. Gimsing, P.; Carlson, K.; Turesson, I.; Fayers, P.; Waage, A.; Vangsted, A.; Mylin, A.; Gluud, C.; Juliusson, G.; Gregersen, H.; et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial. Lancet Oncol. 2010, 11, 973–982. [Google Scholar] [CrossRef]
  58. Pavkovic, M.; Petrushevska, G.; Jovanovic, R.; Karanfilski, O.; Cevreska, L.; Stankovic, S.; Stojanovic, A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. Prilozi 2010, 31, 39–49. [Google Scholar] [PubMed]
  59. Stopeck, A.T.; Lipton, A.; Body, J.J.; Steger, G.G.; Tonkin, K.; de Boer, R.H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D.A.; Viniegra, M.; et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 2010, 28, 5132–5139. [Google Scholar] [CrossRef] [PubMed]
  60. Fizazi, K.; Carducci, M.; Smith, M.; Damião, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011, 377, 813–822. [Google Scholar] [CrossRef]
  61. Quispe, D.; Shi, R.; Burton, G. Osteonecrosis of the jaw in patients with metastatic breast cancer: Ethnic and socio-economic aspects. Breast J. 2011, 17, 510–513. [Google Scholar] [CrossRef] [PubMed]
  62. Ding, X.; Fan, Y.; Ma, F.; Li, Q.; Wang, J.; Zhang, P.; Yuan, P.; Xu, B. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast 2012, 21, 544–549. [Google Scholar] [CrossRef] [PubMed]
  63. Miyazaki, H.; Nishimatsu, H.; Kume, H.; Suzuki, M.; Fujimura, T.; Fukuhara, H.; Enomoto, Y.; Ishikawa, A.; Igawa, Y.; Hirano, Y.; et al. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. BJU Int. 2012, 110, E520–E525. [Google Scholar] [CrossRef] [PubMed]
  64. Smith, M.R.; Saad, F.; Coleman, R.; Shore, N.; Fizazi, K.; Tombal, B.; Miller, K.; Sieber, P.; Karsh, L.; Damião, R.; et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379, 39–46. [Google Scholar] [CrossRef]
  65. Thumbigere-Math, V.; Tu, L.; Huckabay, S.; Dudek, A.Z.; Lunos, S.; Basi, D.L.; Hughes, P.J.; Leach, J.W.; Swenson, K.K.; Gopalakrishnan, R. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am. J. Clin. Oncol. 2012, 35, 386–392. [Google Scholar] [CrossRef] [PubMed]
  66. Rugani, P.; Luschin, G.; Jakse, N.; Kirnbauer, B.; Lang, U.; Acham, S. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin. Oral Investig. 2014, 18, 401–407. [Google Scholar] [CrossRef] [PubMed]
  67. Then, C.; Hörauf, N.; Otto, S.; Pautke, C.; von Tresckow, E.; Röhnisch, T.; Baumann, P.; Schmidmaier, R.; Bumeder, I.; Oduncu, F.S. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 2012, 35, 658–664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Martin, M.; Bell, R.; Bourgeois, H.; Brufsky, A.; Diel, I.; Eniu, A.; Fallowfield, L.; Fujiwara, Y.; Jassem, J.; Paterson, A.H.; et al. Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. Clin. Cancer Res. 2012, 18, 4841–4849. [Google Scholar] [CrossRef] [PubMed]
  69. Henry, D.H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G.V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 2011, 29, 1125–1132. [Google Scholar] [CrossRef] [PubMed]
  70. Saad, F.; Brown, J.E.; Van Poznak, C.; Ibrahim, T.; Stemmer, S.M.; Stopeck, A.T.; Diel, I.J.; Takahashi, S.; Shore, N.; Henry, D.H.; et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 2012, 23, 1341–1347. [Google Scholar] [CrossRef] [PubMed]
  71. Assaf, A.T.; Smeets, R.; Riecke, B.; Weise, E.; Groebe, A.; Blessmann, M.; Steiner, T.; Wikner, J.; Friedrich, R.E.; Heiland, M.; et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013, 33, 3917–3924. [Google Scholar] [PubMed]
  72. Coleman, R.E.; de Boer, R.; Eidtmann, H.; Llombart, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Sleeboom, H.P.; Forbes, J.; Barrios, C.; et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann. Oncol. 2013, 24, 398–405. [Google Scholar] [CrossRef] [PubMed]
  73. Brufsky, A.M.; Sereika, S.M.; Mathew, A.; Tomifumi, O.; Singh, V.; Rosenzweig, M. Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study. Breast J. 2013, 19, 504–511. [Google Scholar] [CrossRef] [PubMed]
  74. Rathbone, E.J.; Brown, J.E.; Marshall, H.C.; Collinson, M.; Liversedge, V.; Murden, G.A.; Cameron, D.; Bell, R.; Spensley, S.; Agrawal, R.; et al. Osteonecrosis of the jaw and oral health–related quality of life after adjuvant zoledronic acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial subprotocol (BIG01/04). J. Clin. Oncol. 2013, 31, 2685–2691. [Google Scholar] [CrossRef] [PubMed]
  75. Barrett-Lee, P.; Casbard, A.; Abraham, J.; Hood, K.; Coleman, R.; Simmods, P.; Timmins, H.; Wheatley, D.; Griffiths, G.; Murray, N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metasta-ses from breast cancer: A randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014, 15, 114–122. [Google Scholar] [CrossRef]
  76. Coleman, R.; Cameron, D.; Dodwell, D.; Bell, R.; Wilson, C.; Rathbone, E.; Keane, M.; Gil, M.; Burkinshaw, R.; Grieve, R.; et al. Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014, 15, 997–1006. [Google Scholar] [CrossRef]
  77. Jackson, G.H.; Morgan, G.J.; Davies, F.E.; Wu, P.; Gregory, W.M.; Bell, S.E.; Szubert, A.J.; Navarro Coy, N.; Drayson, M.T.; Owen, R.G.; et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br. J. Haematol. 2014, 166, 109–117. [Google Scholar] [CrossRef] [PubMed]
  78. Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, G.; Knauer, M.; Moik, M.; Jakesz, R.; Seifert, M.; Taucher, S.; Bjelic-Radisic, V.; et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann. Oncol. 2015, 26, 313–320. [Google Scholar] [PubMed]
  79. Vidal-Real, C.; Pérez-Sayáns, M.; Suárez-Peñaranda, J.M.; Gándara-Rey, J.M.; García-García, A. Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Med. Oral Patol. Oral Cir. Bucal 2015, 20, e267–e272. [Google Scholar] [CrossRef] [PubMed]
  80. Rodrigues, P.; Hering, F.; Imperio, M. Safety of IV Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term follow-up on Prostate Cancer Patients. Clin. Genitourin. Cancer 2015, 13, 199–203. [Google Scholar] [CrossRef] [PubMed]
  81. Stopeck, A.T.; Fizazi, K.; Body, J.J.; Brown, J.E.; Carducci, M.; Diel, I.; Fujiwara, Y.; Martín, M.; Paterson, A.; Tonkin, K.; et al. Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support. Care Cancer 2016, 24, 447–455. [Google Scholar] [CrossRef] [PubMed]
  82. Boquete-Castro, A.; Gómez-Moreno, G.; Calvo-Guirado, J.L.; Aguilar-Salvatierra, A.; Delgado-Ruiz, R.A. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin. Oral Implants Res. 2016, 27, 367–375. [Google Scholar] [CrossRef] [PubMed]
  83. Cheng, A.; Mavrokokki, A.; Carter, G.; Stein, B.; Fazzalari, N.L.; Wilson, D.F.; Goss, A.N. The dental implications of bisphosphonates and bone disease. Aust. Dent. J. 2005, 50, S4–S13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Lazarovici, T.S.; Yahalom, R.; Taicher, S.; Elad, S.; Hardan, I.; Yarom, N. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J. Oral Maxillofac. Surg. 2009, 67, 850–855. [Google Scholar] [CrossRef] [PubMed]
  85. Grötz, K.A.; Diel, I.J. Osteonekrose des Kiefers unter Bisphosphonat-Langzeittherapie. Im Focus Onkol. 2005, 3, 52–55. [Google Scholar]
  86. Abu-Id, M.H.; Warnke, P.H.; Gottschalk, J.; Springer, I.; Wiltfang, J.; Acil, Y.; Russo, P.A.; Kreusch, T. “Bis-phossy jaws”—High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J. Cranio-Maxillo-Fac. Surg. 2008, 36, 95–103. [Google Scholar] [CrossRef] [PubMed]
  87. Otto, S.; Schreyer, C.; Hafner, S.; Mast, G.; Ehrenfeld, M.; Sturzenbaum, S.; Pautke, C. Bisphosphonate-related osteonecrosis of the jaws—Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J. Cranio-Maxillo-Fac. Surg. 2012, 40, 303–309. [Google Scholar] [CrossRef] [PubMed]
  88. Suleman, Y.F.; Meer, S.; Lurie, R. Bisphosphonate-induced osteonecrosis of the jaws: Review, clinical implications and case report. Head Neck Pathol. 2007, 1, 156–164. [Google Scholar] [CrossRef] [PubMed]
  89. Ficarra, G.; Beninati, F.; Rubino, I.; Vannucchi, A.; Longo, G.; Tonelli, P.; Pini Prato, G. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J. Clin. Periodontol. 2005, 32, 1123–1128. [Google Scholar] [CrossRef] [PubMed]
  90. Taylor, T.; Bryant, C.; Popat, S. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King’s College Hospital. Br. Dent. J. 2013, 214, E18. [Google Scholar] [CrossRef] [PubMed]
  91. Saia, G.; Blandamura, S.; Bettini, G.; Tronchet, A.; Totola, A.; Bedogni, G.; Ferronato, G.; Nocini, P.F.; Bedogni, A. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J. Oral Maxillofac. Surg. 2010, 68, 797–804. [Google Scholar] [CrossRef] [PubMed]
  92. Niibe, K.; Ouchi, T.; Iwasaki, R.; Nakagawa, T.; Horie, N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J. Prosthodont. Res. 2015, 59, 3–5. [Google Scholar] [CrossRef] [PubMed]
  93. Rahimi-Nedjat, R.K.; Sagheb, K.; Pabst, A.; Olk, L.; Walter, C. Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw. Dent. J. 2016, 4, 17. [Google Scholar] [CrossRef]
  94. Beninati, F.; Pruneti, R.; Ficarra, G. Bisphosphonate-related osteonecrosis of the jaws (Bronj). Med. Oral Patol. Oral Cir. Bucal 2013, 18, e752–e758. [Google Scholar] [CrossRef] [PubMed]
  95. Sim Ie, W.; Sanders, K.M.; Borromeo, G.L.; Seymour, J.F.; Ebeling, P.R. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. J. Clin. Endocrinol. Metab. 2015, 100, 3887–3893. [Google Scholar] [CrossRef] [PubMed]
  96. Bagan, J.V.; Jimenez, Y.; Gomez, D.; Sirera, R.; Poveda, R.; Scully, C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008, 44, 1088–1089. [Google Scholar] [CrossRef] [PubMed]
  97. Marx, R.E.; Cillo, J.E., Jr.; Ulloa, J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 2007, 65, 2397–2410. [Google Scholar] [CrossRef] [PubMed]
Dentistry 04 00032 g001 550
Figure 1. Published prevalences.
Figure 1. Published prevalences.
Dentistry 04 00032 g001
Dentistry 04 00032 g002 550
Figure 2. Published prevalences in reports until 2009 and since 2010.
Figure 2. Published prevalences in reports until 2009 and since 2010.
Dentistry 04 00032 g002
Table
Table 1. Included studies.
Table 1. Included studies.
YearAuthorStudy DesignDiseasePatients (n)ONJ CasesPrevalence (%)Used Agent
2005Bamias [17]prosbreast ca7022.86Z, PZ, ZI
prosmult myel111119.91Z, PZ, ZI
prosprostate ca4636.52Z, PZ, ZI
Durie [18]web surveymult myel904626.86Z, P
web surveybreast ca299134.35
Guarneri [19]retrobreast ca4836.25P
2006Badros [20]retromult myel340113.24P, Z, PZ
Calvo-Villas [21]retromult myel64710.94Z
Dimopoulos [22]prosmult myel202157.43Z
Sanna [23]prosbreast ca8156.17P, Z
Tosi [24]retromult myel25993.47Z
Zervas [25]prosmult myel2542811.02Z, P, ZP
Ortega [26]?breast ca12621.59Z
2007Aguiar Bujanda [27]cssbreast ca35411.43Z
Corso [28]retromult myel10687.55Z, PZ
García Sáenz [29]prosprostate ca10432.88Z
Jadu [30]retromult myel655213.21P
Ortega [31]retroprostate ca52611.54Z
Petrucci [32]?mult myel311227.07Z, P, PZ
Wang [33]retromult myel292113.77Z, P, Z
retrobreast ca8122.47Z, P, Z
retroprostate ca6922.9Z, P, Z
Lipton [34]prospbreast ca21100D
Pozzi [35]retromult myel1402282Z, PZ
2008Boonyapakorn [36]prosmult myel581017.24P, PZ, IZ, Z
Fehm [37]retrobreast ca233104.29Z, ICPZ
Ibrahim [38]retrobreast ca22052.27PZ, Z
retromult myel5923.39PZ, Z
Walter [39]cssprostate ca43818.6IZ, PZ, Z
Yonemori [40]prospbreast ca1800D
Ellis [41]prospbreast ca10600D
Christodoulou [42]retrobreast ca7522.67Z, I
retroprostate ca1119.1Z, I
Estilo [43]retrobreast ca1341813.43P, Z, PZ
retroprostate ca31412.9P, Z, PZ
retromult myel14564.14P, Z, PZ
Hoff [14]retrobreast ca1338161.2P, Z
retromult myel548132..37P, Z
Montefusco [44]retromult myel17895.06BP
Musto [45]prospmult myel8111.23Z
2009Walter [46]cssbreast ca7545.33Z, PZI
Aragon-Ching [47]prosprostate ca601118.33Z
Cetiner [48]prosmult myel32515.63Z
Crawford [49]retrobreast ca113103.5P, PZ, Z
Dimopoulos [50]prosmult myel1281612.5Z
Haidar [51]retroprostate ca5123.92Z
Ripamonti [52]retrobreast ca590183.05P, PZ, Z
prospbreast ca11221.79P, PZ, Z
Vahtsevanos [53]retrobreast ca1041323.07Z, P, I, PZ, IZ
retromult myel539468.53P, PZ, Z
retroprostate ca4124.88P, Z, ZI
Fizazi [54]prospprostate1700P, Z
prospbreast ca1600P, Z
prospprostate ca3300D
prospbreast ca3000D
Bonomi [55]retrobreast ca23872.94P, PZ, Z
retroprotate ca4612.17P, PZ, Z
Stumpe [56]retromult myel12832.34P, Z, PZ
retrobreast ca24110.41P, Z, PZ
retroprostate ca12810.78P, Z, PZ
2010Walter [16]retromult myel8144.94U, PZ
cssmult myel781620.51Z, PZ, IZ, PZI
Bantis [11]retroprostate ca60915Z
Gimsing [57]retrobreast ca25083.2P normal dose (90 mg)
retrobreast ca25220.79P low dose (30 mg)
Pakovic [58]retromult myel19021.05P, PI, I
Stopeck [59]prospbreast ca1020201.96D
prospbreast ca1013141.38Z
2011Fizazi [60]prospprostate ca950222.32D
prospprostate ca951121.26Z
Quispe [61]retrobreast ca110109.09Z
2012Ding [62]retrobreast ca18110.55P, I, Z
Miyazaki [63]retroprostate ca11198.11Z
Smith [64]prospprostate ca716334.61D
Thumbigere-Math [65]retrobreast ca19084.21P, PZ, Z
retromult myel8367.23P, PZ, Z
retroprostate ca8422.38P, PZ, Z
Rugani [66]retrobreast ca48510.42Z
Then [67]retromult myel1202319.17P, Z, I
Martin [68]prospbreast ca102600D
Henry [69] + Saad [70]prospmult myel18063.33D,Z
2013Assaf [71]retrobreast ca9599.47P, I, Z, ZI, PI
retromult myel42511.9P, I, Z, ZI, PI
Coleman [72]prospbreast ca106550.47Z
Brufsky [73]retrobreast ca15963.77P, Z, PZ
retrobreast ca6211.61P, Z, PZ
Rathbone [74]prospbreast ca1681261.55Z
2014Barrett-Lee [75]prospbreast ca69791.29Z
Coleman [76]prospbreast ca1685261.54Z
Jackson [77]prospmult myel981363.67Z
Gnant [78]prospbreast ca90000Z
2015Vidal-Real [79]retroprostate ca43920.93Z
retrobreast ca15426.67Z
retromult myel1800Z
Rodrigues [80]prospprostate ca32420.62Z
2016Stopeck [81]prospbreast ca318206.29D
prospbreast ca334185.39ZD
prospprostate ca147128.16D
prospprostate ca11875.93ZD
Abbreviations: prosp (prospective), retro (retrospective), ccs (cross-sectional study), ? (unknown), ca (cancer), mult myel (multiple myeloma), Z (zoldronate), P (pamidonate), I (ibandronate), D (denosumab).
Table
Table 2. Weighted prevalences in breast cancer, prostate cancer, and multiple myeloma patients.
Table 2. Weighted prevalences in breast cancer, prostate cancer, and multiple myeloma patients.
Breast CancerProstate CancerMultiple MyelomaTotal
nCasesprevnCasesprevnCasesprevnCasesprev
−200955311562.82%732446.01%67963445.06%13,0595444.17%
2010+11,1011921.73%35041173.34%1773985.53%16,3784072.49%
Total16,6323482.09%42361613.80%85694425.16%29,4379513.23%
Abbreviations: n (number of patients); prev (prevalence); Cases (number of patients with ONJ).

Share and Cite

MDPI and ACS Style

Rugani, P.; Walter, C.; Kirnbauer, B.; Acham, S.; Begus-Nahrman, Y.; Jakse, N. Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent. J. 2016, 4, 32. https://doi.org/10.3390/dj4040032

AMA Style

Rugani P, Walter C, Kirnbauer B, Acham S, Begus-Nahrman Y, Jakse N. Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dentistry Journal. 2016; 4(4):32. https://doi.org/10.3390/dj4040032

Chicago/Turabian Style

Rugani, Petra, Christian Walter, Barbara Kirnbauer, Stephan Acham, Yvonne Begus-Nahrman, and Norbert Jakse. 2016. "Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma" Dentistry Journal 4, no. 4: 32. https://doi.org/10.3390/dj4040032

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop